Transcriptomic and metabolomic profiles of pulmonary arterial hypertension patients

Pulmonary arterial hypertension (PAH) is a progressive disorder that can lead to right ventricular failure and severe consequences. Despite extensive efforts, limited progress has been made in preventing the progression of PAH. Understanding its pathogenesis is crucial for developing better treatments. The aim of this study is to explore the pathogenesis of PAH by transcriptomic and metabolomic analyses. Lung tissue specimens were collected from eight adult patients with PAH and eight non-PAH adult patients as the control group undergoing pulmonary lobectomy or partial pulmonary lobectomy at the First Affiliated Hospital, Sun Yat-sen University between February 2023 and April 2023. The lung tissue samples in the control group were collected at a site remote from tumor foci of early-stage lung cancer patients. The diagnosis of PAH was defined as a pulmonary artery systolic pressure > 35 mmHg detected by noninvasive echocardiography. RNA sequencing for transcriptomic profiling was conducted using an Illumina Novaseq6000. The liquid chromatography-tandem mass spectrometry system was used for non-targeted metabolomic profiling. T1 – T8 represent PAH samples 1 – 8, and N1 – N8 represent control samples 1 – 8.